Taken together, these data point to IFN-α and RhoC inhibition as being capable of reducing cancer cell invasion in a cumulative fashion—a potential combination strategy that could be more effective in RhoC-driven phenotypes, such as inflammatory breast cancer, as there was clearly a larger effect on adhesion and invasion in SUM 149 crRhoC cells treated with IFN-α compared to MDA 231 crRhoC cells. The gene discussed is IFNA2; the disease is inflammatory breast carcinoma.